Armistice Capital LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 54.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 336,000 shares of the company’s stock after selling 400,000 shares during the period. Armistice Capital LLC’s holdings in Novo Nordisk A/S were worth $17,096,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the stock. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at $25,000. WealthCollab LLC lifted its holdings in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares in the last quarter. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Maseco LLP bought a new stake in Novo Nordisk A/S in the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $29,000. Institutional investors own 11.54% of the company’s stock.
Analysts Set New Price Targets
NVO has been the subject of several analyst reports. Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target for the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $65.56.
Novo Nordisk A/S News Summary
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Novo Nordisk said it will seek Chinese regulatory approval for its oral Wegovy pill “very soon,” which could expand its obesity franchise into one of the world’s largest pharmaceutical markets and help offset recent concerns about GLP-1 supply constraints. Article Title
- Positive Sentiment: Some commentary and broker coverage are framing Novo Nordisk as a beaten-down or fairly valued leader rather than a broken story, and the stock continues to draw investor attention, suggesting valuation-sensitive buyers may be stepping in. Article Title
- Neutral Sentiment: Brokerage coverage remains lukewarm, with Novo Nordisk carrying an average “Hold” rating, which suggests analysts are not seeing a near-term catalyst strong enough to turn sentiment decisively bullish. Article Title
- Negative Sentiment: Multiple reports said a hacking group stole more than a terabyte of data and attempted a $25 million extortion, while leaked information and exposed clinical-trial patient data raise cybersecurity, privacy, and regulatory risks for Novo Nordisk. Article Title
- Negative Sentiment: The breach comes as Novo Nordisk is already dealing with GLP-1 production and supply strain, so investors may worry that operational issues and reputational damage could pressure execution. Article Title
Novo Nordisk A/S Stock Performance
Shares of NVO opened at $43.55 on Thursday. The stock has a 50-day simple moving average of $42.69 and a 200-day simple moving average of $45.91. The stock has a market capitalization of $194.45 billion, a PE ratio of 10.22, a PEG ratio of 3.89 and a beta of 0.78. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $74.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, analysts predict that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Read More
- Five stocks we like better than Novo Nordisk A/S
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
